Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939026 | 0.81 | KMT2A (0.63) | TSHRTDP1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL14980131 | 0.79 | KMT2A (0.60) | TSHRTDP1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL647041 | 0.79 | TSHR (0.71) | TSHRTDP1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL1559659 | 0.79 | KMT2A (0.65) | TSHRTDP1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL8626581 | 0.79 | ALDH1A1 (0.80) | TSHRTDP1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL9764561 | 0.78 | KMT2A (0.68) | L3MBTL1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL28459510 | 0.77 | ALDH1A1 (0.64) | TDP1L3MBTL1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL17545031 | 0.76 | LMNA (0.62) | TSHRKMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL692347 | 0.76 | ALDH1A1 (0.66) | SMN1; SMN2HPGDALDH1A1HSD17B10GAA | |
| SCHEMBL7126868 | 0.76 | HPGD (0.56) | L3MBTL1KMT2ASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2007147834-A1 | GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | IFNG, IRF3, IL2 | TSHR 2239/4885TDP1 2642/4885L3MBTL1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.